Wellington Management Group LLP Lowers Stake in GSK PLC Sponsored ADR $GSK

Key Points

• Wellington Management Group LLP has reduced its stake in GSK PLC by 8.4%, now owning approximately 1.92 million shares worth $74.3 million.
• GSK reported earnings of $1.23 per share for the last quarter, exceeding analysts' expectations of $1.12, alongside a revenue of $10.64 billion.
• The company recently announced a quarterly dividend of $0.4206 per share, which reflects an annualized dividend yield of 4.2%.

Wellington Management Group LLP decreased its holdings in shares of GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 8.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,917,890 shares of the pharmaceutical company's stock after selling 176,215 shares during the period. Wellington Management Group LLP owned about 0.09% of GSK worth $74,299,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of GSK. Brighton Jones LLC bought a new position in GSK in the 4th quarter worth $528,000. Barclays PLC raised its position in GSK by 84.2% in the 4th quarter. Barclays PLC now owns 49,628 shares of the pharmaceutical company's stock worth $1,678,000 after purchasing an additional 22,689 shares during the period. Guggenheim Capital LLC raised its position in GSK by 6.2% in the 4th quarter. Guggenheim Capital LLC now owns 15,053 shares of the pharmaceutical company's stock worth $509,000 after purchasing an additional 881 shares during the period. Dimensional Fund Advisors LP raised its position in GSK by 0.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,598,570 shares of the pharmaceutical company's stock worth $87,884,000 after purchasing an additional 18,492 shares during the period. Finally, TD Waterhouse Canada Inc. grew its stake in GSK by 6.8% in the 4th quarter. TD Waterhouse Canada Inc. now owns 20,963 shares of the pharmaceutical company's stock worth $709,000 after acquiring an additional 1,332 shares in the last quarter. Institutional investors own 15.74% of the company's stock.

Analyst Ratings Changes

A number of research firms have recently issued reports on GSK. Berenberg Bank reiterated a "hold" rating on shares of GSK in a research note on Tuesday, June 3rd. Wall Street Zen raised shares of GSK from a "hold" rating to a "buy" rating in a report on Sunday, August 3rd. Six analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Reduce" and a consensus price target of $37.38.

GSK Price Performance

NYSE GSK traded down $0.29 during trading hours on Thursday, hitting $39.63. 1,204,778 shares of the company's stock traded hands, compared to its average volume of 5,089,470. GSK PLC Sponsored ADR has a 52-week low of $31.72 and a 52-week high of $44.26. The company has a market capitalization of $80.71 billion, a PE ratio of 18.36, a PEG ratio of 1.73 and a beta of 0.51. The company has a debt-to-equity ratio of 1.07, a current ratio of 0.87 and a quick ratio of 0.57. The firm's 50-day moving average is $38.35 and its 200-day moving average is $38.18.

GSK (NYSE:GSK - Get Free Report) last posted its earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share for the quarter, beating the consensus estimate of $1.12 by $0.11. The company had revenue of $10.64 billion for the quarter, compared to analyst estimates of $7.92 billion. GSK had a net margin of 10.81% and a return on equity of 49.22%. GSK's revenue was up 1.3% on a year-over-year basis. During the same period in the previous year, the business posted $0.43 EPS. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. Equities analysts forecast that GSK PLC Sponsored ADR will post 4.14 EPS for the current fiscal year.

GSK Cuts Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 9th. Shareholders of record on Friday, August 15th will be issued a dividend of $0.4206 per share. The ex-dividend date is Friday, August 15th. This represents a $1.68 dividend on an annualized basis and a yield of 4.2%. GSK's dividend payout ratio is 77.78%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.